Polyrizon reports mucoadhesion results for intranasal naloxone hydrogel

Polyrizon (PLRZ) announced new preclinical data showing its proprietary naloxone hydrogel adheres to nasal tissue longer than an approved and marketed intranasal naloxone spray product. Using an established ex-vivo rabbit nasal mucosa model, researchers evaluated the persistence of Polyrizon’s hydrogel formulation versus commercial product by applying each formulation to mucosal tissue and washing with Simulated Nasal Electrolyte Solution over a 30-minute period. Quantification of residual fluorescence revealed that Polyrizon’s hydrogel maintained higher values of the fluorescence marker when compared to the commercial product, with differences reaching high statistical significance, indicating notably stronger and more durable mucosal retention. The results showed that Polyrizon’s Trap and Target hydrogel exhibited significantly higher mucoadhesion levels compared to the commercial product, supporting potentially prolonged contact at the nasal deposition site and potentially enhancing bioavailabilit